People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a head-to-head clinical trial, Lilly said in a news release Wednesday.  

The study, which Lilly funded, is the first randomized, controlled clinical trial comparing the two rival weight loss drugs. Previous studies have shown Zepbound outperforms Wegovy for weight loss, however, those weren’t considered true comparisons as they relied on looking back at existing data.